[go: up one dir, main page]

DE69710526D1 - Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von bipolaren Störungen - Google Patents

Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von bipolaren Störungen

Info

Publication number
DE69710526D1
DE69710526D1 DE69710526T DE69710526T DE69710526D1 DE 69710526 D1 DE69710526 D1 DE 69710526D1 DE 69710526 T DE69710526 T DE 69710526T DE 69710526 T DE69710526 T DE 69710526T DE 69710526 D1 DE69710526 D1 DE 69710526D1
Authority
DE
Germany
Prior art keywords
xanomeline
thiadiazol
methylpyridine
hexyloxy
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69710526T
Other languages
English (en)
Other versions
DE69710526T2 (de
Inventor
Franklin Porter Bymaster
Harlan Edgar Shannon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE69710526D1 publication Critical patent/DE69710526D1/de
Application granted granted Critical
Publication of DE69710526T2 publication Critical patent/DE69710526T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nonmetallic Welding Materials (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Electrolytic Production Of Non-Metals, Compounds, Apparatuses Therefor (AREA)
  • Processing Of Solid Wastes (AREA)
  • Press Drives And Press Lines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69710526T 1996-08-01 1997-07-25 Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von bipolaren Störungen Expired - Lifetime DE69710526T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2290096P 1996-08-01 1996-08-01

Publications (2)

Publication Number Publication Date
DE69710526D1 true DE69710526D1 (de) 2002-03-28
DE69710526T2 DE69710526T2 (de) 2002-10-02

Family

ID=21812011

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69710526T Expired - Lifetime DE69710526T2 (de) 1996-08-01 1997-07-25 Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von bipolaren Störungen

Country Status (19)

Country Link
EP (1) EP0821955B1 (de)
JP (1) JP2000515547A (de)
KR (1) KR20000029647A (de)
CN (1) CN1226165A (de)
AT (1) ATE213413T1 (de)
AU (1) AU716972B2 (de)
BR (1) BR9710901A (de)
CA (1) CA2261802C (de)
CZ (1) CZ27299A3 (de)
DE (1) DE69710526T2 (de)
DK (1) DK0821955T3 (de)
EA (1) EA199900174A1 (de)
ES (1) ES2171838T3 (de)
HU (1) HUP9904578A2 (de)
IL (1) IL128280A0 (de)
NO (1) NO990436L (de)
PL (1) PL331407A1 (de)
PT (1) PT821955E (de)
WO (1) WO1998005324A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
WO2011011060A1 (en) * 2009-07-22 2011-01-27 Puretech Ventures Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
JP7096441B2 (ja) 2018-09-28 2022-07-05 カルナ セラピューティックス，インコーポレイテッド ムスカリン受容体活性化によって改善される障害を処置するための組成物及び方法
CN111430027B (zh) * 2020-03-18 2023-04-28 浙江大学 基于肠道微生物的双相情感障碍生物标志物及其筛选应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
US5376668A (en) * 1990-08-21 1994-12-27 Novo Nordisk A/S Heterocyclic compounds
EP0734259B1 (de) * 1993-08-19 2002-06-12 Novo Nordisk A/S Verwendung von Piperidin-Derivaten in der Behandlung von Schizophrenie
US5646289A (en) * 1994-10-24 1997-07-08 Eli Lilly And Company Heterocyclic compounds and their preparation and use
US5488056A (en) * 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety
EP0709094B1 (de) * 1994-10-31 2000-04-05 Eli Lilly And Company Tetrahydropyridin Oxadiazol- oder -Thiadiazol-Verbindung zur Behandlung von Angstzuständen

Also Published As

Publication number Publication date
PL331407A1 (en) 1999-07-19
CN1226165A (zh) 1999-08-18
EP0821955A2 (de) 1998-02-04
EP0821955B1 (de) 2002-02-20
NO990436D0 (no) 1999-01-29
HUP9904578A2 (hu) 2000-06-28
CZ27299A3 (cs) 1999-08-11
JP2000515547A (ja) 2000-11-21
EP0821955A3 (de) 1998-04-22
WO1998005324A1 (en) 1998-02-12
EA199900174A1 (ru) 1999-08-26
ES2171838T3 (es) 2002-09-16
NO990436L (no) 1999-01-29
AU716972B2 (en) 2000-03-09
AU4046897A (en) 1998-02-25
DE69710526T2 (de) 2002-10-02
CA2261802C (en) 2006-11-07
IL128280A0 (en) 1999-11-30
PT821955E (pt) 2002-07-31
KR20000029647A (ko) 2000-05-25
ATE213413T1 (de) 2002-03-15
DK0821955T3 (da) 2002-03-18
CA2261802A1 (en) 1998-02-12
BR9710901A (pt) 1999-08-17

Similar Documents

Publication Publication Date Title
FI935529A0 (fi) Aminometylensubstituerade icke-aromatiska heterocykliska foereningar
DE60012751D1 (de) Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
DE69729946D1 (de) Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia
ES2194960T3 (es) N-(2-sustituido-3-(2-aminoetil)-1h-indol-5-il)-amidas como nuevos agonistas de 5-ht1f.
ATE425750T1 (de) Verwendung von triglyceriden mit mittellangen ketten zur behandlung und vorbeugung der alzheimerschen erkrankung
ATE209490T1 (de) Substanz p antagonisten zur behandlung von erbrechen
DE60014136D1 (de) Sapogenin derivate zur behandlung von kognitiven störungen
ATE112166T1 (de) Verwendung von 1-(3-(dimethylamino)propyl>-1- phenylphthalenen zur behandlung zerebrovaskulärer störungen.
ATE212548T1 (de) Behandlung und prophylaxe von pankreatitis
ATE231131T1 (de) Verbindungen mit wachtumshormon freisetzenden eigenschaften
DE69710526D1 (de) Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von bipolaren Störungen
DE3887598D1 (de) Pharmazeutisch verwendbare polymorphe Modifikation von Buspiron.
ATE222491T1 (de) Melatonin-derivate zur verwendung in der behandlung von schlafstörungen
DE69816244D1 (de) Verwendung von 2-Aryl-3-aroylbenzo(b)thiophene zur Behandlung des Oestrogenenthaltungssyndroms
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
DE69713571D1 (de) Verwendung von (+)-alpha-(2,3-dimethoxyphenyl)-1(2-(4-fluorophenyl)ethyl-4-piperidinmethanol zur behandlung von depressionen und bipolaren erkrankungen
DE59109225D1 (de) Verwendung von pyridylmethylsulfinyl-1h-benzimidazol derivaten zur behandlung durch helicobacter verursachter erkrankungen
DE69904849D1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen
NO20003481L (no) FremgangsmÕte for behandling av COPD
ATE470671T1 (de) Verbindungen mit wachstumshormon-freisetzender eigenschaft
ATE283269T1 (de) 5-(heteroaryl)alkyl)-3-oxo-pyrido(1,2- a)benzimidazol-4-carboxamid (pbi) derivate zur behandlung von störungen des zentralen nervensystems
DE69823650D1 (de) Azasteroidverbindung zur behandlung oder vorbeugung von prostatakrebs
DE69221649D1 (de) Lacidipin zur Behandlung der Arteriosklerosis
ATE264840T1 (de) Azetidincarboxamid-derivate zur behandlung von zns störungen
ATE299021T1 (de) Verwendung von oxazolidinonderivaten zur behandlung von psoriasis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN